vs
Side-by-side financial comparison of MacKenzie Realty Capital, Inc. (MKZR) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.
Relay Therapeutics, Inc. is the larger business by last-quarter revenue ($7.0M vs $4.6M, roughly 1.5× MacKenzie Realty Capital, Inc.).
MacKenzie Realty Capital, Inc. is a U.S.-based real estate investment firm focused on acquiring, owning, and managing a diversified portfolio of income-generating commercial and residential real estate assets. It targets properties in high-growth regional markets across the U.S. to deliver consistent long-term returns to its investors.
Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.
MKZR vs RLAY — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.6M | $7.0M |
| Net Profit | $-4.5M | — |
| Gross Margin | — | — |
| Operating Margin | -102.5% | — |
| Net Margin | -97.4% | — |
| Revenue YoY | -42.8% | — |
| Net Profit YoY | -0.4% | — |
| EPS (diluted) | $-2.97 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.6M | $7.0M | ||
| Q3 25 | $4.5M | $0 | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | $4.3M | $7.7M | ||
| Q4 24 | $8.0M | $0 | ||
| Q3 24 | $5.0M | $0 | ||
| Q2 24 | $4.5M | $0 | ||
| Q1 24 | $4.1M | $10.0M |
| Q4 25 | $-4.5M | — | ||
| Q3 25 | $-3.0M | $-74.1M | ||
| Q2 25 | $-6.0M | — | ||
| Q1 25 | $-6.1M | $-77.1M | ||
| Q4 24 | $-4.5M | — | ||
| Q3 24 | $-7.4M | $-88.1M | ||
| Q2 24 | $-2.5M | $-92.2M | ||
| Q1 24 | $-2.9M | $-81.4M |
| Q4 25 | -102.5% | — | ||
| Q3 25 | -76.8% | — | ||
| Q2 25 | -117.3% | — | ||
| Q1 25 | -136.4% | -1105.2% | ||
| Q4 24 | -56.7% | — | ||
| Q3 24 | -150.3% | — | ||
| Q2 24 | -58.1% | — | ||
| Q1 24 | -65.6% | -903.0% |
| Q4 25 | -97.4% | — | ||
| Q3 25 | -67.1% | — | ||
| Q2 25 | -125.1% | — | ||
| Q1 25 | -142.6% | -1003.6% | ||
| Q4 24 | -55.5% | — | ||
| Q3 24 | -149.6% | — | ||
| Q2 24 | -55.6% | — | ||
| Q1 24 | -72.3% | -813.3% |
| Q4 25 | $-2.97 | — | ||
| Q3 25 | $-2.20 | $-0.43 | ||
| Q2 25 | $-8.16 | — | ||
| Q1 25 | $-0.47 | $-0.46 | ||
| Q4 24 | $-3.93 | — | ||
| Q3 24 | $-6.10 | $-0.63 | ||
| Q2 24 | $-9.20 | $-0.69 | ||
| Q1 24 | $-0.26 | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.3M | $84.0M |
| Total DebtLower is stronger | $145.6M | — |
| Stockholders' EquityBook value | $51.8M | $567.1M |
| Total Assets | $238.1M | $621.3M |
| Debt / EquityLower = less leverage | 2.81× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.3M | $84.0M | ||
| Q3 25 | $4.9M | $91.6M | ||
| Q2 25 | $3.6M | — | ||
| Q1 25 | $5.1M | $93.5M | ||
| Q4 24 | $6.5M | $124.3M | ||
| Q3 24 | $10.7M | $152.4M | ||
| Q2 24 | $11.9M | $134.1M | ||
| Q1 24 | $15.5M | $152.9M |
| Q4 25 | $145.6M | — | ||
| Q3 25 | $142.7M | — | ||
| Q2 25 | $135.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $14.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $117.3M | — | ||
| Q1 24 | — | — |
| Q4 25 | $51.8M | $567.1M | ||
| Q3 25 | $56.7M | $607.7M | ||
| Q2 25 | $59.9M | — | ||
| Q1 25 | $66.7M | $721.1M | ||
| Q4 24 | $68.3M | $777.8M | ||
| Q3 24 | $73.4M | $838.9M | ||
| Q2 24 | $82.4M | $681.7M | ||
| Q1 24 | $86.3M | $745.8M |
| Q4 25 | $238.1M | $621.3M | ||
| Q3 25 | $241.7M | $670.0M | ||
| Q2 25 | $236.0M | — | ||
| Q1 25 | $237.1M | $799.4M | ||
| Q4 24 | $236.4M | $871.3M | ||
| Q3 24 | $243.5M | $930.1M | ||
| Q2 24 | $233.1M | $772.5M | ||
| Q1 24 | $226.1M | $841.4M |
| Q4 25 | 2.81× | — | ||
| Q3 25 | 2.52× | — | ||
| Q2 25 | 2.26× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.22× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.6M | $-235.5M |
| Free Cash FlowOCF − Capex | — | $-235.9M |
| FCF MarginFCF / Revenue | — | -3370.0% |
| Capex IntensityCapex / Revenue | — | 5.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-622.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.6M | $-235.5M | ||
| Q3 25 | $-2.0M | $-62.1M | ||
| Q2 25 | $-1.7M | — | ||
| Q1 25 | $-2.6M | $-73.2M | ||
| Q4 24 | $1.9M | $-249.1M | ||
| Q3 24 | $644.4K | $-75.1M | ||
| Q2 24 | $-595.5K | $-65.8M | ||
| Q1 24 | $743.3K | $-50.3M |
| Q4 25 | — | $-235.9M | ||
| Q3 25 | — | $-62.1M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-73.6M | ||
| Q4 24 | — | $-251.1M | ||
| Q3 24 | — | $-75.3M | ||
| Q2 24 | — | $-65.8M | ||
| Q1 24 | — | $-52.1M |
| Q4 25 | — | -3370.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -958.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -520.7% |
| Q4 25 | — | 5.9% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 17.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
